No title
Studies on mantle cell lymphoma (MCL) emphasize that patients with progression of disease (POD) ≤24 months have inferior prognosis compared to patients with later POD. This population-based study assessed the impact of POD on overall survival (OS) by timing of progression and first-line treatment. A total of 1186 MCL patients diagnosed 2006–2018 were identified in the Swedish lymphoma register. PO
